<DOC>
	<DOCNO>NCT00713518</DOCNO>
	<brief_summary>The aim study evaluate whether PF-04523655 effective treatment neovascular/wet AMD dose .</brief_summary>
	<brief_title>Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV ( MONET Study ) .</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Males female age 50 year older active primary recurrent subfoveal choroidal neovascularization ( CNV ) secondary agerelated macular degeneration ( AMD ) . Active CNV define leakage detect FFA OCT . Note : Female subject 50 60 year age must amenorrheic least 2 year serum FSH level within laboratory reference range postmenopausal woman The total area CNV ( include classic occult component ) encompass within lesion must 50 % total lesion area . The total lesion size ≤12 disc area . Best correct visual acuity use ETDRS protocol 20/40 20/320 ( letter score ≤73 ) study eye screen visit . Best correct visual acuity score fellow eye 20/400 good ( letter score ≥19 ) Screening Visit . Note : Only one eye treat ( study eye ) duration study . In event eye eligible study entry study eye select investigator subject . The nonstudy eye may treat approve AMD therapy Subject retinal central subfield thickness ≥250µm measure use Stratus OCT . Prior treatment verteporfin photodynamic therapy , externalbeam radiation therapy , transpupillary thermotherapy study eye Previous subfoveal focal laser photocoagulation study eye Laser photocoagulation ( juxtafoveal extrafoveal ) study eye within 1 month precede Baseline History vitrectomy , submacular surgery surgical intervention AMD study eye Previous participation study investigational drug treatment administer 1 month precede Baseline visit systemic glucocorticoid , ocular periocular steroid ( eg , triamcinolone , anecortave acetate ) , antiangiogenic drug pegaptanib ( Macugen ) , ranibizumab ( Lucentis ) , bevacizumab ( Avastin ) study eye Subretinal hemorrhage study eye involve fovea , size hemorrhage either 50 % total lesion area 1 disc area size CNV either eye etiology , eg , ocular histoplasmosis , trauma , pathologic myopia Presence subfoveal scar Retinal pigment epithelial tear involve macula study eye</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>AMD Age Related Macular Degeneration Choroidal Neovascularization Monet</keyword>
</DOC>